484 related articles for article (PubMed ID: 19584289)
1. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
[TBL] [Abstract][Full Text] [Related]
2. Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site.
Talavera A; Mackenzie J; Garrido G; Friemann R; López-Requena A; Moreno E; Krengel U
Mol Immunol; 2011 Jul; 48(12-13):1578-85. PubMed ID: 21592580
[TBL] [Abstract][Full Text] [Related]
3. Active and inactive conformations of the epidermal growth factor receptor.
Ferguson KM
Biochem Soc Trans; 2004 Nov; 32(Pt 5):742-5. PubMed ID: 15494003
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
[TBL] [Abstract][Full Text] [Related]
5. Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers.
Kozer N; Kelly MP; Orchard S; Burgess AW; Scott AM; Clayton AH
Biochemistry; 2011 May; 50(18):3581-90. PubMed ID: 21495621
[TBL] [Abstract][Full Text] [Related]
6. Novel monoclonal antibodies recognizing the active conformation of epidermal growth factor receptor.
Ise N; Omi K; Miwa K; Honda H; Higashiyama S; Goishi K
Biochem Biophys Res Commun; 2010 Apr; 394(3):685-90. PubMed ID: 20226763
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
8. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity.
Holbrook MR; Slakey LL; Gross DJ
Biochem J; 2000 Nov; 352 Pt 1(Pt 1):99-108. PubMed ID: 11062062
[TBL] [Abstract][Full Text] [Related]
9. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.
Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ
Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629
[TBL] [Abstract][Full Text] [Related]
10. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations.
Berger C; Krengel U; Stang E; Moreno E; Madshus IH
J Immunother; 2011 Sep; 34(7):550-5. PubMed ID: 21760527
[TBL] [Abstract][Full Text] [Related]
11. The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.
Ward CW; Lawrence MC; Streltsov VA; Adams TE; McKern NM
Trends Biochem Sci; 2007 Mar; 32(3):129-37. PubMed ID: 17280834
[TBL] [Abstract][Full Text] [Related]
12. Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display.
Chao G; Cochran JR; Wittrup KD
J Mol Biol; 2004 Sep; 342(2):539-50. PubMed ID: 15327953
[TBL] [Abstract][Full Text] [Related]
13. Structure of the extracellular region of HER3 reveals an interdomain tether.
Cho HS; Leahy DJ
Science; 2002 Aug; 297(5585):1330-3. PubMed ID: 12154198
[TBL] [Abstract][Full Text] [Related]
14. Ligand binding induces a conformational change in epidermal growth factor receptor dimers.
Walker F; Rothacker J; Henderson C; Nice EC; Catimel B; Zhang HH; Scott AM; Bailey MF; Orchard SG; Adams TE; Liu Z; Garrett TP; Clayton AH; Burgess AW
Growth Factors; 2012 Dec; 30(6):394-409. PubMed ID: 23163584
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of a cocaine-binding antibody.
Larsen NA; Zhou B; Heine A; Wirsching P; Janda KD; Wilson IA
J Mol Biol; 2001 Aug; 311(1):9-15. PubMed ID: 11469854
[TBL] [Abstract][Full Text] [Related]
16. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.
Boland WK; Bebb G
Expert Opin Biol Ther; 2009 Sep; 9(9):1199-206. PubMed ID: 19624281
[TBL] [Abstract][Full Text] [Related]
17. A basic peptide within the juxtamembrane region is required for EGF receptor dimerization.
Aifa S; Aydin J; Nordvall G; Lundström I; Svensson SP; Hermanson O
Exp Cell Res; 2005 Jan; 302(1):108-14. PubMed ID: 15541730
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of Thr654 but not Thr669 within the juxtamembrane domain of the EGF receptor inhibits calmodulin binding.
Aifa S; Frikha F; Miled N; Johansen K; Lundström I; Svensson SP
Biochem Biophys Res Commun; 2006 Aug; 347(2):381-7. PubMed ID: 16793002
[TBL] [Abstract][Full Text] [Related]
19. Specificity determinants of a novel Nck interaction with the juxtamembrane domain of the epidermal growth factor receptor.
Hake MJ; Choowongkomon K; Kostenko O; Carlin CR; Sönnichsen FD
Biochemistry; 2008 Mar; 47(10):3096-108. PubMed ID: 18269246
[TBL] [Abstract][Full Text] [Related]
20. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.
Johns TG; Mellman I; Cartwright GA; Ritter G; Old LJ; Burgess AW; Scott AM
FASEB J; 2005 May; 19(7):780-2. PubMed ID: 15774576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
